BR0215873A - Composto, composição farmacêutica, método de inibição de desenvolvimento de células microbianas, método para o tratamento de condições microbianas em mamìferos e processo para a preparação de um composto - Google Patents

Composto, composição farmacêutica, método de inibição de desenvolvimento de células microbianas, método para o tratamento de condições microbianas em mamìferos e processo para a preparação de um composto

Info

Publication number
BR0215873A
BR0215873A BR0215873-6A BR0215873A BR0215873A BR 0215873 A BR0215873 A BR 0215873A BR 0215873 A BR0215873 A BR 0215873A BR 0215873 A BR0215873 A BR 0215873A
Authority
BR
Brazil
Prior art keywords
compound
preparing
compounds
cell development
formula
Prior art date
Application number
BR0215873-6A
Other languages
English (en)
Inventor
Sudershan Kumar Arora
Neelima Sinha
Sanjay Jain
Ram Shankar Upadhayaya
Gourhari Jana
Shankar Ajay
Rakesh Kumar Sinha
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of BR0215873A publication Critical patent/BR0215873A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/335Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Communicable Diseases (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"COMPOSTO, COMPOSTO FARMACêUTICA, MéTODO DE INIBIçãO DE DESENVOLVIMENTO DE CéLULAS MICROBIANAS, MéTODO PARA O TRATAMENTO DE CONDIçõES MICROBIANAS EM MAMìFEROS E PROCESSO PARA A PREPARAçãO DE UM COMPOSTO". A presente invenção se refere a novos derivados de pirrola de fórmula (I) e seus sais de adição ácida farmaceuticamente aceitáveis dotados de atividade antimicobacteriana superior contra cepas clinicamente sensíveis assim como cepas resistentes de Mycobacterium tuberculosis, assim como dotados de menor toxicidade em comparação aos compostos conhecidos. A presente invenção também refere-se ao uso dos compostos de fórmula (I) para o tratamento de tuberculose latente incluindo tuberculose Resistente a Múltiplas Drogas (MDR TB). Métodos de preparação dos novos compostos, composições farmacêuticas contendo os novos compostos e metodos de tratamento de MDR TB por meio da administração dos compostos de fórmula (I).
BR0215873-6A 2002-09-20 2002-09-20 Composto, composição farmacêutica, método de inibição de desenvolvimento de células microbianas, método para o tratamento de condições microbianas em mamìferos e processo para a preparação de um composto BR0215873A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2002/000189 WO2004026828A1 (en) 2002-09-20 2002-09-20 Pyrrole derivatives as antimycobacterial compounds

Publications (1)

Publication Number Publication Date
BR0215873A true BR0215873A (pt) 2005-07-12

Family

ID=32012142

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0215873-6A BR0215873A (pt) 2002-09-20 2002-09-20 Composto, composição farmacêutica, método de inibição de desenvolvimento de células microbianas, método para o tratamento de condições microbianas em mamìferos e processo para a preparação de um composto

Country Status (19)

Country Link
US (2) US7691837B2 (pt)
EP (2) EP1857442A3 (pt)
JP (1) JP2006503837A (pt)
CN (1) CN1668584A (pt)
AP (1) AP1979A (pt)
AU (1) AU2002343200B2 (pt)
BR (1) BR0215873A (pt)
CA (1) CA2499701A1 (pt)
EA (1) EA012461B1 (pt)
HR (1) HRP20050347A2 (pt)
HU (1) HUP0500598A2 (pt)
IS (1) IS7795A (pt)
MX (1) MXPA05003022A (pt)
NO (1) NO20051901L (pt)
NZ (1) NZ539449A (pt)
RS (1) RS20050231A (pt)
TN (1) TNSN05080A1 (pt)
UA (1) UA81640C2 (pt)
WO (1) WO2004026828A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491721B2 (en) * 2004-05-12 2009-02-17 Lupin Limited Antimycobacterial pharmaceutical composition
AU2006215399B2 (en) * 2005-02-18 2010-12-09 Astrazeneca Ab Antibacterial piperidine derivatives
ITRM20050094A1 (it) 2005-03-04 2006-09-05 Univ Siena Derivati del 1-(1,5-di(4-clorofenil)-2metil-1h-3-pirroli)metil)-4-metilpiperazina (bm 212), procedimento per la loro produzione e uso di essi come antitubercolari.
CA2604388A1 (en) * 2005-04-11 2006-10-19 Lupin Limited Preparation of [2-methyl-5-phenyl-3-(piperazin-1-ylmethyl)] pyrrole derivatives
CN101190894A (zh) * 2006-11-23 2008-06-04 中国人民解放军军事医学科学院毒物药物研究所 脂肪酸合成酶抑制剂及其制药用途
EP2311457A1 (en) 2009-10-19 2011-04-20 Forschungszentrum Borstel Pharmaceutical compositions for treating infections with drug resistant mycobacteria
HUP1000033A2 (en) * 2010-01-21 2011-07-28 Uratim Kft Piperazine derivatives useful against mycobacteriums
CN102802650B (zh) * 2010-03-22 2014-05-21 科学与工业技术研究委员会 刺果藤属物种的抗结核病组合物
KR100998556B1 (ko) 2010-04-08 2010-12-07 강원대학교산학협력단 신규한 다치환 피롤 유도체와 이의 제조방법
CN103122370B (zh) * 2011-11-21 2014-06-18 华中农业大学 一种三嗪类化合物作为抗结核分枝杆菌抑制剂的应用
WO2014009766A2 (en) 2012-07-13 2014-01-16 Corning Incorporated Methods and apparatuses for producing laminated glass sheets
IN2013DE01663A (pt) 2013-06-03 2015-07-10 Council Scient Ind Res
KR102126576B1 (ko) 2018-09-19 2020-06-24 주식회사 대웅제약 4-메톡시 피롤 유도체의 제조 방법
RU2767542C1 (ru) * 2021-05-24 2022-03-17 Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) Противотуберкулезное средство на основе 4-((гет)ароил)-3- гидрокси-1-(2-гидроксифенил)-5-(фенилтио)-1,5-дигидро-2Н-пиррол-2-онов

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2986564A (en) * 1959-02-20 1961-05-30 Rips Richard Pyrrole compounds
US3246010A (en) * 1963-06-10 1966-04-12 Parke Davis & Co 1, 5-diaryl-2-pyrrole propanols and ethers
US3168531A (en) * 1963-06-12 1965-02-02 Parke Davis & Co 1-aryl-5-(p-lower alkoxyphenyl)-pyrrole-2-propionic acid compounds
US3168532A (en) * 1963-06-12 1965-02-02 Parke Davis & Co 1, 5-diarylpyrrole-2-propionic acid compounds
GB1263940A (en) * 1968-08-02 1972-02-16 Innothera Lab Sa 0-phenyl-pyrroles

Also Published As

Publication number Publication date
US20050107370A1 (en) 2005-05-19
EP1857442A3 (en) 2008-02-06
EA012461B1 (ru) 2009-10-30
EP1546097A1 (en) 2005-06-29
TNSN05080A1 (en) 2007-05-14
CN1668584A (zh) 2005-09-14
IS7795A (is) 2005-04-11
EP1857442A2 (en) 2007-11-21
US7763602B2 (en) 2010-07-27
AU2002343200B2 (en) 2009-08-13
NZ539449A (en) 2007-08-31
WO2004026828A1 (en) 2004-04-01
MXPA05003022A (es) 2005-05-27
EA200500500A1 (ru) 2006-02-24
NO20051901L (no) 2005-04-19
US7691837B2 (en) 2010-04-06
JP2006503837A (ja) 2006-02-02
RS20050231A (en) 2007-06-04
HRP20050347A2 (en) 2006-03-31
HUP0500598A2 (en) 2006-02-28
AP2005003277A0 (en) 2005-06-30
UA81640C2 (ru) 2008-01-25
AU2002343200A1 (en) 2004-04-08
AP1979A (en) 2009-03-20
CA2499701A1 (en) 2004-04-01
US20080242676A1 (en) 2008-10-02

Similar Documents

Publication Publication Date Title
TNSN05080A1 (en) NOVEL ANTIMYCOBACTERIAL COMPOUNDS (as filed) AND PYRROLE DERIVATIVES AS ANTIMYCOBACTERIAL COMPOUNDS (as published)
BR0317435A (pt) Derivados de pirimidina para o tratamento do crescimento celular anormal
BR0008202A (pt) Derivados de quinolin-2-ona substituìdos com heteroarilas úteis como agentes contra o câncer
BRPI0911476A2 (pt) compostos ativadores de glicoquinase de piridazinona, composição farmaceutica, uso dos compostos, método para tratamento de uma enfermidade e/ou distúbio metabólico e processo para a preparação dos compostos
BR0009486A (pt) Compostos que contêm uma amida, utilização desses compostos, composição farmacêutica, processo para o tratamento profilático ou terapêutico de, diabetes do tipo ii e processo para a preparação dos compostos
BRPI9913138B8 (pt) derivado de quinolin-2-ona substituído com alquinila e composição farmacêutica contendo o mesmo
BRPI0414330A (pt) composto, processo para preparação do mesmo, métodos para produção de um efeito antibacteriano, para inibição de dna girase bacteriana, e para tratamento de uma infecção bacteriana em um animal de sangue quente, uso de um composto, e, composição farmacêutica
BR0213522A (pt) Composto, composição farmacêutica, métodos de inibir a hiv integrase e para prevenir ou tratar a infecção pelo hiv ou para prevenir, tratar ou retardar o inìcio da aids em um paciente, e, combinação útil para tratar ou prevenir a infecção pelo hiv ou para prevenir, tratar ou retardar o inìcio da aids
BR0317524A (pt) Compostos derivados de pirrolopirimidina, composição farmacêutica, processo para as suas preparações e respectivo uso
BRPI0514036A (pt) composto, sais farmaceuticamente aceitáveis do mesmo, diastereÈmeros, enanciÈmeros ou misturas do mesmo, uso de um composto, composição farmacêutica, método para a terapia de depressão em um animal de sangue quente, e, processo para preparar um composto
BRPI0414514A (pt) uso de um composto, composto, e, composições farmacêuticas
ATE279192T1 (de) Die verwendung eines benzimidazoles zur herstellung eines medikamentes zur krebsvorbeugung
BRPI0310032B8 (pt) derivados de benzoxazina, seus usos e seus processos de produção, e composição farmacêutica
NO20002099L (no) 6,11-bro-erytromycinderivater
BR0308144A (pt) Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
BRPI0414780B8 (pt) composto, uso do mesmo, composição farmacêutica, e, método para preparar um composto
BR9908125A (pt) Composto, composto dimérico, composição farmacêutica, uso do composto, processo compreendendo inibir células de câncer, e, processo terapêutico
UA99492C2 (ru) Производные 1,3-дигидро-5-изобензофуранкарбонитрила и его фармацевтическая композиция для лечения преждевременной эякуляции
CR20220472A (es) Compuesto de oxazolidinona y métodos de uso de este como agente antibacteriano
NO20080816L (no) Anvendelse av delmopinol ved behandling av kviser
BR0317433A (pt) Derivados bicìclicos para o tratamento do crescimento celular anormal
BR0315995A (pt) Composto, uso de um composto composição farmacêutica, métodos para a terapia da dor, de distúrbios gastrointestinais, e da ansiedade em um animal de sangue quente, e, processo para preparar um composto
BRPI0411226A (pt) composto, uso de um composto, composição farmacêutica, e, método para a terapia contra dor em um animal de sangue quente, e para a preparação de um composto
BR0214937A (pt) Processo de preparação de derivados de equinocandina
KR880007462A (ko) 빈뇨치료용 프로피오페논 유도체

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2167 DE 17/07/2012.